Modeling the cost-effectiveness of the next-generation COVID-19 mRNA-1283 vaccine in the United States.
Abstract
Study results suggest mRNA-1283 may represent a highly cost-effective strategy (considering a 100, 000-150, 000 per QALY willingness-to-pay threshold) to reduce COVID-19 burden. Based on rVE assumptions made, mRNA-1283 was estimated to dominate originally-licensed mRNA vaccines in this recommended population. mRNA-1283 may provide a valuable option to optimize US COVID-19 immunization programs and protect those most vulnerable.
What are the key findings of this study?
The mRNA-1283 vaccine could be a smart choice for fighting COVID-19. It may help people get well and save costs compared to older vaccines. This means it could better protect those who need it most. More effective vaccines mean fewer sick people and a healthier community! 💉
Key Points
Objective
The research aims to evaluate the cost-effectiveness of the mRNA-1283 vaccine compared to existing vaccines for COVID-19.
Methods
- Utilized cost-effectiveness modeling techniques to analyze vaccine strategies.
- Considered a $100,000-150,000 per QALY willingness-to-pay threshold.
- Analyzed relative vaccine effectiveness (rVE) assumptions between mRNA-1283 and originally licensed mRNA vaccines.
Results
- mRNA-1283 may be more cost-effective than initial mRNA vaccines.
- Estimated to provide significant health benefits at a lower cost per quality-adjusted life year (QALY).
- Potential to optimize US COVID-19 immunization programs, especially for vulnerable populations.